The observed differences in CARIS properties suggest that CD19/20/22CAR T-cells exhibit favorable CARIS cytoskeletal properties, which could enhance their immunoactivity upon engaging BL-ALL cells. This evidence concerns the gene CD19 and Burkitt lymphoma.